Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

People with Down syndrome (DS) are at high risk of developing Alzheimer disease (AD) with aging. The diagnosis and treatment trials are hampered by a lack of reliable blood biomarkers. Plasma neurofilament light chain (NfL) is one of the established biomarkers of AD, suggesting that it may be useful as an indicator of dementia in DS patients. The aims of this study were: 1) to examine whether plasma levels of NfL in DS patients are correlated with decreased adaptive behavior scores one year after sample collection, and 2) to compare plasma levels of NfL in adults with DS and an age-matched healthy control population. In this study, plasma levels of NfL in 24 patients with DS and 24 control participants were measured by the single-molecule immunoarray (Simoa) method. We observed significantly increased plasma NfL levels in the DS compared with the control group. There was a significant correlation between age and levels of plasma NfL in both groups. This age-dependent elevation was steeper in the DS compared with the control group. Moreover, elevated plasma NfL was associated with decreased adaptive behavior scores one year later, after age-adjustment. Previously reported blood-based biomarkers available in Simoa for DS, plasma total tau and phosphorylated tau, were not significantly correlated with the annual decrement of adaptive behavior scores after age-adjustment. These results suggest that plasma NfL has the potential to serve as an objective biomarker to predict dementia in adult DS patients.

What this study adds

Evidence grade: Low

The record lists 24 participants. In 24 adults with Down syndrome and 24 controls, plasma neurofilament light was higher in the Down syndrome group and higher levels were linked to decreased adaptive behavior one year later. This is a small study suggesting a possible prognostic blood marker, not a treatment or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Shinomoto, M., Kasai, T., Tatebe, H., Kondo, M., Ohmichi, T., Morimoto, M., et al. (2019). Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients. PloS one. https://doi.org/10.1371/journal.pone.0211575

Vancouver

Shinomoto M, Kasai T, Tatebe H, Kondo M, Ohmichi T, Morimoto M, et al. Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients. PloS one. 2019. doi:10.1371/journal.pone.0211575. PMID: 30951523.

BibTeX

@article{shinomoto2019-30951523,
  author  = {Shinomoto, M. and Kasai, T. and Tatebe, H. and Kondo, M. and Ohmichi, T. and Morimoto, M. and Chiyonobu, T. and Terada, N. and others},
  title   = {{Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients}},
  journal = {PloS one},
  year    = {2019},
  doi     = {10.1371/journal.pone.0211575},
  pmid    = {30951523},
  url     = {https://doi.org/10.1371/journal.pone.0211575}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In 24 adults with Down syndrome and 24 controls, plasma neurofilament light was higher in the Down syndrome group and higher levels were linked to decreased adaptive behavior one year later. This is a small study suggesting a possible prognostic blood marker, not a treatment or prevention.

Study details

How this study scored 46/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 46 of 100.46 of 100 points earned54 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (PloS one)
Journal's citation record 4 / 4 PLoS ONE: journal h-index 594 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2019 — within 10 year(s) of the newest study here
Sample size 1 / 4 24 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 31 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 3.4 citations a year over 9 year(s) since 2019
Impact for its field and year 3 / 6 Cited 4.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 3 other studies in this library
Still being cited 1 / 4 Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Takahiko Tokuda: h-index 49 (OpenAlex, whole career)
Institution's track record 0 / 3 Lancaster University: institution h-index 694 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 30951523)
Free to read 2 / 2 Free to read
Total 46 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in Biomarkers from nearby years

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →